Preferred Label : Osanetant;
NCIt definition : An orally bioavailable, brain penetrating, non-peptide neurokinin/tachykinin 3 receptor
(NK1-receptor; NK3R; NK-3R) antagonist, that may potentially be used to treat vasomotor
symptoms (VMS) in menopausal woman and in men on androgen deprivation therapy (ADT)
and to suppress the production of certain hormones. Upon oral administration, osanetant
targets, competitively binds to and blocks the activity of NK3R in the central nervous
system (CNS), thereby inhibiting NK3R-mediated signal transduction and may prevent
certain menopausal symptoms such as hot flashes and VMS in men deprived of androgen.
Neurokinin-mediated signaling may increase during hormone deficiency and may cause
hot flashes. In addition, osanetant may, by inhibiting NK3R, suppress secretion of
various hormones, such as testosterone, luteinizing hormone (LH) and follicle-stimulating
hormone (FSH). By suppressing testosterone production, osanetant may inhibit the proliferation
of hormone-sensitive prostate cancer.;
UNII : K7G81N94DT;
InChIKey : DZOJBGLFWINFBF-UMSFTDKQSA-N;
CAS number : 160492-56-8;
Molecule name : SR-142,801; ACER 801; SR-14280; ACER-801; SR 14280;
NCI Metathesaurus CUI : CL1382751;
Origin ID : C170264;
UMLS CUI : C1138576;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
